Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Interest & Investment Income (2016)

Heron Therapeutics (HRTX) has disclosed Interest & Investment Income for 4 consecutive years, with $119000.0 as the latest value for Q4 2016.

  • For the quarter ending Q4 2016, Interest & Investment Income changed N/A year-over-year to $119000.0, compared with a TTM value of $445000.0 through Dec 2016, changed N/A, and an annual FY2025 reading of $1.9 million, down 45.13% over the prior year.
  • Interest & Investment Income was $119000.0 for Q4 2016 at Heron Therapeutics, up from $111000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $119000.0 in Q4 2016 and bottomed at -$209000.0 in Q3 2013.
  • Average Interest & Investment Income over 3 years is -$69818.2, with a median of -$146000.0 recorded in 2012.
  • Peak annual rise in Interest & Investment Income hit 44.49% in 2012, while the deepest fall reached 6000.0% in 2012.
  • Year by year, Interest & Investment Income stood at -$197000.0 in 2012, then fell by 6.09% to -$209000.0 in 2013, then skyrocketed by 156.94% to $119000.0 in 2016.
  • Business Quant data shows Interest & Investment Income for HRTX at $119000.0 in Q4 2016, $111000.0 in Q3 2016, and $97000.0 in Q2 2016.